drugset / Trial / NCT04068896
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
RandomizedSequentialQuadruple-blindTreatment
Summary
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
Timeline
- Start
- 2019-10-16
- Primary completion
- 2023-09-21
- Completion
- 2024-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NGM120 | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | NGM120 | Monoclonal antibody | 100 mg | Subcutaneous |
| Background | Abraxane | Small molecule | 125 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |